Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms.

ABSTRACT:

Objectives

To ensure the accuracy of susceptibility testing methods for ceftazidime/avibactam.

Methods

The performances of the Etest (bioMérieux), 30/20 μg disc (Hardy diagnostics) and 10/4 μg disc (Mast Group) were evaluated against the reference broth microdilution (BMD) method for 102 clinically relevant Gram-negative organisms: 69 ceftazidime- and meropenem-resistant Klebsiella pneumoniae and 33 MDR non-K. pneumoniae. Essential and categorical agreement along with major and very major error rates were determined according to CLSI guidelines.

Results

A total of 78% of isolates were susceptible to ceftazidime/avibactam. None of the three methods met the defined equivalency threshold against all 102 organisms. The Etest performed the best, with categorical agreement

SUBMITTER: Wenzler E 

PROVIDER: S-EPMC6657273 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature